Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ACELYRIN, INC. - Common Stock (NQ:SLRN)

2.150 -0.020 (-0.92%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ACELYRIN, INC. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease
From ACELYRIN, INC.
Via GlobeNewswire
ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024
From ACELYRIN, INC.
Via GlobeNewswire
ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive
From ACELYRIN, INC.
Via GlobeNewswire
SLRN Stock Earnings: Acelyrin Misses EPS for Q2 2024
SLRN stock results show that Acelyrin missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
SLRN Stock Earnings: Acelyrin Beats EPS for Q1 2024
SLRN stock results show that Acelyrin beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
SLRN Stock Earnings: Acelyrin Beats EPS for Q4 2023
SLRN stock results show that Acelyrin beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
ACELYRIN, INC. to Participate in Upcoming Investor Conferences
From ACELYRIN, INC.
Via GlobeNewswire
Fabrinet Posts Strong Earnings, Joins Amer Sports, Hawaiian Holdings And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Acelyrin Cuts Workforce, Deprioritizes Former Lead Drug Izokibep
Acelyrin reports promising Phase 3 results for izokibep in hidradenitis suppurativa, announces a strategic focus on lonigutamab. 
Via Benzinga
Ouster Reports Weak Sales, Joins Brinker International And Other Big Stocks Moving Lower In Wednesday Pre-Market Session
Via Benzinga
ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results
From ACELYRIN, INC.
Via GlobeNewswire
ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024
From ACELYRIN, INC.
Via GlobeNewswire
Why Arhaus Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024
From ACELYRIN, INC.
Via GlobeNewswire
ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024
From ACELYRIN, INC.
Via GlobeNewswire
ACELYRIN ALERT: Bragar Eagel & Squire, P.C. is Investigating Acelyrin, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
From ACELYRIN, INC.
Via GlobeNewswire
ACELYRIN, INC. Announces Leadership Transition
From ACELYRIN, INC.
Via GlobeNewswire
ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024
From ACELYRIN, INC.
Via GlobeNewswire
ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights
From ACELYRIN, INC.
Via GlobeNewswire
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
From Avalo Therapeutics
Via GlobeNewswire
Investors Cheer Acelyrin's Stock, Its Second Lead Candidate Shows Clinical Benefit In Thyroid Eye Disease Patients
Acelyrin releases Phase 1/2 trial results of lonigutamab. Rapid improvements in eye bulge and double vision. Well-tolerated with no serious adverse events. Phase 2b/3 trial slated for the second half... 
Via Benzinga
ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease
From ACELYRIN, INC.
Via GlobeNewswire
Acelyrin's Lead Drug Candidate Hits Primary Goal In Late-Stage Psoriatic Arthritis Study
Acelyrin reports positive Phase 2b/3 trial results for izokibep in psoriatic arthritis, achieving ACR50 at week 16 with high statistical significance. Long-term data in hidradenitis suppurativa show... 
Via Benzinga
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
From ACELYRIN, INC.
Via GlobeNewswire
ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients
From ACELYRIN, INC.
Via GlobeNewswire
ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications
From ACELYRIN, INC.
Via GlobeNewswire
Acelyrin (SLRN) Investor Update: Kaplan Fox & Kilsheimer LLP Reminds Acelyrin Investors of a Class Action Lawsuit and Upcoming Deadline
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
SLRN DEADLINE TOMORROW: ROSEN, A LEADING NATIONAL FIRM, Encourages ACELYRIN, INC. Investors with Losses to Secure Counsel Before Important January 16 Deadline in Securities Class Action - SLRN
WHY: NEW YORK, NY - (NewMediaWire) - January 15, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ACELYRIN, INC. (NASDAQ: SLRN) between May 4, 2023 and... 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
SLRN DEADLINE NOTICE: ROSEN, A LONGSTANDING LAW FIRM, Encourages ACELYRIN, INC. Investors to Secure Counsel Before Important January 16 Deadline in Securities Class Action - SLRN
WHY: NEW YORK, NY - (NewMediaWire) - January 14, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ACELYRIN, INC. (NASDAQ: SLRN) between May 4, 2023 and... 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.